{
  "id": "CD015536.PUB2",
  "draft": "Is entecavir effective and safe for children and adults with chronic hepatitis B compared to no treatment or a placebo?\n\nWe looked at the benefits and harms of entecavir for children and adults with chronic hepatitis B. We wanted to know if entecavir is better than no treatment or a placebo in reducing serious health problems and improving quality of life.\n\n- We are very uncertain if entecavir reduces serious harmful effects compared to no treatment or a placebo. The evidence is not strong enough to be sure.\n- We found very low-certainty evidence, meaning we are very uncertain about the results, and more research is needed to fully understand the effects of entecavir.\n- Future research should focus on addressing the limitations of current evidence, including the lack of data on quality of life and the need for longer-term follow-up.\n\nWhat is chronic hepatitis B and why is it a problem?\nChronic hepatitis B is a major public health concern worldwide. It is a liver infection caused by the hepatitis B virus (a type of virus that attacks the liver) that can lead to serious health problems, including liver damage, liver cancer, and death. Entecavir is one of the antiviral therapy options (a type of treatment that fights viruses) used to treat chronic hepatitis B.\n\nWhat did the review authors want to find out?\nThe review authors wanted to evaluate the benefits and harms of entecavir compared to no treatment or placebo in children and adults with chronic hepatitis B. They aimed to find out whether entecavir is effective in reducing the risk of serious health problems, such as death from any cause and serious harmful effects, and improving quality of life.\n\nHow did we conduct this review?\nWe searched for studies comparing entecavir with no treatment or placebo in people with chronic hepatitis B, summarized their results, and rated our confidence in the evidence.\n\nWhat did we find?\nWe found 22 studies that involved 2940 people with chronic hepatitis B. The studies were conducted over a period of 5 weeks to 228 weeks. We are very uncertain if entecavir reduces serious harmful effects compared to no treatment or a placebo. It is unclear if entecavir has an effect on death from any cause. There is a lack of data on quality of life.\n\nWhat are the limitations of the evidence?\nThe limitations of the evidence are that participants may have known which treatment they received, not all studies reported all outcomes of interest, and the studies were very small.\n\nHow up-to-date is the evidence?\nThe evidence is up to date to July 2024.",
  "metrics": [
    {
      "linguistic_evaluation": {
        "words": {
          "value": 453,
          "rating": "within_limit",
          "direction": null,
          "feedback": null
        },
        "sentences": {
          "value": 24,
          "rating": "info",
          "direction": null,
          "feedback": null
        },
        "words_per_sentence": {
          "value": 18.875,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "passive_voice": {
          "value": 9,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "active_voice": {
          "value": 39,
          "rating": "P50",
          "direction": "higher_better",
          "feedback": null
        },
        "pronouns": {
          "value": 26,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "nominalization": {
          "value": 18,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "nouns": {
          "value": 128,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "flesch_reading_ease": {
          "value": 54.707338576158946,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "flesch_kincaid_grade": {
          "value": 10.31782836644592,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "automated_readability_index": {
          "value": 9.311672185430464,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "coleman_liau_index": {
          "value": 9.228079470198676,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "gunning_fog_index": {
          "value": 15.40871964679912,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "lix": {
          "value": 48.676324503311264,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "rix": {
          "value": 5.625,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "smog_index": {
          "value": 11.831760866327848,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "dale_chall_readability": {
          "value": 7.036089624724063,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "complex_words_dc": {
          "value": 175,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "complex_words": {
          "value": 89,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "long_words": {
          "value": 135,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        }
      },
      "word_count_status": {
        "word_count": 453,
        "limit": 850,
        "status": "within_limit",
        "message": "Word count: 453 ✓ WITHIN LIMIT (≤850 words)"
      },
      "summary": {
        "P25_count": 9,
        "P50_count": 2,
        "P75_count": 7,
        "P90_count": 0,
        "P10_count": 0,
        "BEYOND_P90_count": 0,
        "BELOW_P10_count": 0,
        "total_evaluated": 18,
        "P25_percentage": 50,
        "P50_percentage": 11.11111111111111,
        "P75_percentage": 38.88888888888889,
        "P90_percentage": 0,
        "P10_percentage": 0,
        "BEYOND_P90_percentage": 0,
        "BELOW_P10_percentage": 0,
        "best_quartile_rate": 88.88888888888889,
        "overall_assessment": "HIGHLY CONFORMS TO TYPICAL PLS PATTERNS"
      }
    }
  ],
  "evaluation": [
    {
      "grade": "NOT_APPROVED",
      "feedback": "This draft is statistically strong and meets all critical requirements. However, it is NOT_APPROVED because a few key improvements are needed to ensure maximum clarity for the reader. Here are the top 3 recommendations:\n\n1. **Use 'we' consistently instead of switching to 'the review authors'.** Using 'we' throughout makes the summary more direct and easier to follow, as recommended by the style guide.\n    *   **Problem:** 'What did the review authors want to find out? The review authors wanted to evaluate...'\n    *   **Suggestion:** 'What did we want to find out? We wanted to evaluate...'\n\n2. **Strengthen the key messages to be more informative and less repetitive.** The first two bullet points currently say very similar things. Combining them and adding key details from the main findings would be more helpful for readers.\n    *   **Problem:** The first two messages repeat 'we are very uncertain' without adding much new information. They also omit the findings on mortality and quality of life.\n    *   **Suggestion:** Consider revising the key messages to be more like this:\n        - 'We are very uncertain if entecavir reduces serious harmful effects or deaths compared to no treatment or a placebo, as the evidence we found is of very low certainty.'\n        - 'No studies reported on how entecavir affects a person's quality of life.'\n        - 'More and better research is needed, especially studies that follow people for longer.'\n\n3. **Define the term 'placebo' for non-medical readers.** This term is used in the title and throughout the text but is never explained in the body of the text.\n    *   **Problem:** A reader may not know what a placebo is, which is essential for understanding the review's comparison.\n    *   **Suggestion:** Add a simple definition the first time you use the word in the main text, for example: '...compared to no treatment or placebo (a dummy treatment)...'",
      "pls_evaluation_summary": "The linguistic analysis shows the draft highly conforms to typical PLS patterns. All 18 metrics fall within the typical or best-quartile ranges for Cochrane Plain Language Summaries. For example, the average sentence length is excellent at 18.88 words (P25), and the Flesch-Kincaid Grade Level is 10.32 (P25). This indicates a strong statistical foundation for readability. The editorial feedback therefore focuses on nuanced clarity issues not captured by the metrics, such as consistency and the completeness of explanations for key terms."
    }
  ]
}